USPTO serial 79397427
PLURI
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- CREEF, DAVIS W
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).
Need help with PLURI?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Alexander Lazouski
Alexander Lazouski Lazouski IP LLC14726 Bowfin Terrace, Suite 1Lakewood Ranch, FL 34202United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biological preparations for use in industry and science; bioengineered cells for use in industry and science; bioengineered human T cells for use in industry and science; biological tissue, namely, human and animal cells from placentas for use in industry and science; biological tissue, namely, human and animal cells from placentas for use in the manufacture of cosmetic and aesthetic products; biological tissue, namely, human and animal cells from placentas for use in manufacturing biological cosmetic preparations for prevention of hair loss; isolated plant cells, their extracts, and components being botanical extracts, other than essential oils, for use in industry and science; biological tissue, namely, isolated and cultivated adherent cells from placenta tissue for use industry and science; biological tissue, namely, isolated and cultivated adherent stromal cells derived from placentas of multiple donors for use in industry and science; biological tissue, namely, isolated and cultivated mammal cells, their extracts and components for use in industrial manufacture of foodstuffs; biological tissue, namely, isolated and cultivated fish cells and sea food being marine animal cells for use in industrial manufacture of foodstuffs; biological tissue, namely, isolated and cultivated plant cells and their extracts, other than essential oils, for use in industrial manufacture of foodstuffs | ACTIVE | — |
| 005 | Cells and biological preparations intended for medical and clinical use for the treatment of cardiovascular diseases, Critical Limb Ischemia (CLI), muscle regeneration, Acute Radiation Syndrome (ARS), Delayed Effects of Acute Radiation Exposure (DEARE), hematological deficiencies, and pathogenic infectious diseases; bioengineered cells and bioengineered tissue for medical and clinical use for the treatment of cancer; bioengineered cells for use in immunotherapies for treatment of cancer in the nature of solid tumors, and pathogenic infectious diseases; bioengineered human T cells for medical and clinical use; human cells from placentas for medical and clinical use; dietary supplements based on human cells from placentas for cosmetic and aesthetic use; dietary supplements and medical preparations based on human cells from placentas for use in prevention of hair loss; isolated plant cells, their extracts and components being plant extracts, other than essential oils, for medical and clinical use; isolated and cultivated adherent cells from placenta tissue for medical and clinical use; isolated and cultivated adherent stromal cells derived from placentas of multiple donors for medical and clinical use; isolated and cultivated plant cells, their extracts and components being plant extracts, other than essential oils, for medical and clinical use and preparations containing the same for the treatment of inflammatory skin conditions, skin regeneration following burns and environmental damage, for wound healing, for treating arthritis, for maintaining and supporting gut health, for boosting immunity, and for improving general energy levels | ACTIVE | — |
| 042 | Scientific and technological services, namely, scientific research relating to isolation and culturing of animal cells and plant cells and to animal and plant tissues isolation and culturing, to biological preparations intended for medical, clinical, and scientific use of cultured cells and their extracts, to bioengineered cells and tissues, to bioengineered cells for use in immunotherapy for cancer and other infectious diseases, to bioengineered human T cells, to isolated and cultivated human and animal placentas cells, to isolated plant cells and their extracts, to isolated and cultivated adherent cells from placenta tissue, to isolated and cultivated adherent stromal cells derived from placentas of multiple donors, to isolated and cultivated mammal cells, their extracts and preparations containing them, to isolated and cultivated fish cells and sea food cells and preparations containing the same, to isolated and cultivated plant cells and their extracts and preparations containing the same, to research, development and testing services in the fields of mass production of animal and plant cells, and to research, development and testing services in the fields of large scale production of various cells in bioreactors | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 29, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 29, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 23, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 2, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 4, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 4, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 4, 2026 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jul 28, 2026 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jul 28, 2026 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 28, 2026 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 30, 2026 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Nov 30, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Nov 20, 2025 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Nov 12, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 12, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| May 19, 2025 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| May 19, 2025 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| May 19, 2025 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Apr 14, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 14, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 14, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 14, 2025 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| Apr 14, 2025 | PETG | PETITION TO REVIVE-GRANTED | — |
| Apr 14, 2025 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Feb 12, 2025 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Feb 12, 2025 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Aug 18, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 30, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 29, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 2, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 1, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 24, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 20, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 20, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 13, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |